Use of florbetapir-PET for imaging beta-amyloid pathologyChristopher M Clark
Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA
JAMA 305:275-83. 2011
..The ability to identify and quantify brain β-amyloid could increase the accuracy of a clinical diagnosis of Alzheimer disease...
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer diseaseWilliam T Hu
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, USA
Neurology 79:897-905. 2012
..Here we aim to determine plasma biomarkers associated with AD in 2 independent cohorts and validate the findings in the multicenter Alzheimer's Disease Neuroimaging Initiative (ADNI)...
- Alzheimer's disease pattern of brain atrophy predicts cognitive decline in Parkinson's disease
Daniel Weintraub
Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104 3339, USA
Brain 135:170-80. 2012
..In addition, an Alzheimer's disease pattern of brain atrophy may be a preclinical biomarker of cognitive decline in Parkinson's disease...
- Plasma epidermal growth factor levels predict cognitive decline in Parkinson disease
Alice S Chen-Plotkin
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Ann Neurol 69:655-63. 2011
..Most people with Parkinson disease (PD) eventually develop cognitive impairment (CI). However, neither the timing of onset nor the severity of cognitive symptoms can be accurately predicted. We sought plasma-based biomarkers for CI in PD...
- T(1ρ) MRI in Alzheimer's disease: detection of pathological changes in medial temporal lobe
Mohammad Haris
CMROI, SBIA, Center for Neurodegenerative Disease Research, Department of Radiology, University of Pennsylvania, Philadelphia, PA 19104 6100, USA
J Neuroimaging 21:e86-90. 2011
....
- Correlation of amyloid PET ligand florbetapir F 18 binding with Aβ aggregation and neuritic plaque deposition in postmortem brain tissue
Seok Rye Choi
Avid Radiopharmaceutical Inc, 3711 Market Street, 7th Floor, Philadelphia, PA 19104, USA
Alzheimer Dis Assoc Disord 26:8-16. 2012
..This study used human autopsy brain tissue to evaluate the correlation between in vitro florbetapir F 18 binding and Aβ density measured by established neuropathologic methods...
- Amyloid imaging in Alzheimer's disease: comparison of florbetapir and Pittsburgh compound-B positron emission tomography
David A Wolk
Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA
J Neurol Neurosurg Psychiatry 83:923-6. 2012
..Florbetapir-F18 recently demonstrated in vivo correlation with postmortem Aβ histopathology, but has not been directly compared with PiB-C11...
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort studyChristopher M Clark
Avid Radiopharmaceuticals, Philadelphia, PA, USA
Lancet Neurol 11:669-78. 2012
..We therefore prospectively compared the sensitivity and specificity of amyloid PET imaging with neuropathology at autopsy...
- Phosphorylated tau/amyloid beta 1-42 ratio in ventricular cerebrospinal fluid reflects outcome in idiopathic normal pressure hydrocephalus
Sunil Patel
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
Fluids Barriers CNS 9:7. 2012
..abstract:..
- Neurodegeneration across stages of cognitive decline in Parkinson disease
Daniel Weintraub
Department of Psychiatry, University of Pennsylvania, 3615 Chestnut St, Ste 330, Philadelphia, PA 19104, USA
Arch Neurol 68:1562-8. 2011
..To assess regions and patterns of brain atrophy in patients with Parkinson disease (PD) with normal cognition (PD-NC), mild cognitive impairment (PD-MCI), and dementia-level cognitive deficits (PDD)...
- Ethnoracial differences in the clinical characteristics of Alzheimer's disease at initial presentation at an urban Alzheimer's disease center
Melissa Gartenberg Livney
From the Penn Memory Center, University of Pennsylvania, Philadelphia, PA 19104, USA
Am J Geriatr Psychiatry 19:430-9. 2011
....
- Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease
William T Hu
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Acta Neuropathol 120:385-99. 2010
....
- Lack of shunt response in suspected idiopathic normal pressure hydrocephalus with Alzheimer disease pathology
Roy Hamilton
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA
Ann Neurol 68:535-40. 2010
....
- T1rho (T1ρ) MR imaging in Alzheimer's disease and Parkinson's disease with and without dementia
Mohammad Haris
Department of Radiology, Center for Magnetic Resonance and Optical Imaging, University of Pennsylvania, B1 Stellar Chance Laboratories, 422 Curie Boulevard, Philadelphia, PA 19104 6100, USA
J Neurol 258:380-5. 2011
..The serial measurement of T(1ρ) in both AD and PD may provide the nature of disease progression and may contribute to their early diagnosis...
- Comparison of xMAP and ELISA assays for detecting cerebrospinal fluid biomarkers of Alzheimer's disease
Li San Wang
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA, USA
J Alzheimers Dis 31:439-45. 2012
....
- Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup
Magdalena Korecka
Department Pathology and Laboratory Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA
J Chromatogr B Analyt Technol Biomed Life Sci 878:2209-16. 2010
..1g of tissue for 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha)-VI, respectively, for the brain tissue method. No ion suppression or enhancement of the detection of 8-isoPGF(2alpha), 8,12-isoPF(2alpha)-VI or both internal standards was found...
- Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
John Q Trojanowski
Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Alzheimers Dement 6:230-8. 2010
..Further studies in ADNI will refine this model and render the biomarkers studied in ADNI more applicable to routine diagnosis and to clinical trials of disease modifying therapies...
